1. January, 2008
Evolva led consortium receives a € 3.4 million Cancer research grant from EC
Evolva led consortium received € 3.4 million for funding a three year cancer research program on protein-protein interaction. The project brings together some of Europe's leading biotech SME's and several highly recognized academic institutes. By combining distinct chemical approaches and testing them on different targets a series of innovative small-ligand tools and libraries that allow new approaches to the inhibition of PPI in cancer will be developed. The project will begin January 2007.
About Evolva. Evolva develops small molecule drugs based upon proprietary genetic chemistry technologies. Founded in 2004, it currently has pre-clinical stage compounds in the anti-infective and cardiovascular/metabolic disease space, and third party discovery collaborations in cancer, antiviral and immunomodulators. Evolva employs c. 70 people in Switzerland, India and Denmark. For more information see www.evolva.com and www.cappellabio.eu.